Amphastar Pharmaceuticals Inc banner

Amphastar Pharmaceuticals Inc
NASDAQ:AMPH

Watchlist Manager
Amphastar Pharmaceuticals Inc Logo
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Watchlist
Price: 21.91 USD 0.14%
Market Cap: $966m

Wall St Price Targets

AMPH Price Targets Summary
Amphastar Pharmaceuticals Inc

Wall Street analysts forecast AMPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMPH is 22.95 USD with a low forecast of 20.2 USD and a high forecast of 31.5 USD.

Lowest Forecast
Price Target
20.2 USD
8% Downside
Average Forecast
Price Target
22.95 USD
5% Upside
Highest Forecast
Price Target
31.5 USD
44% Upside
Amphastar Pharmaceuticals Inc Competitors:
Price Targets

Revenue
Forecast

10% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
10% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 6 years is 3%.

Gross Profit
Forecast

11% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
11% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 11%. The projected CAGR for the next 3 years is 6%.

Operating Income
Forecast

13% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-22%
Average Miss
13% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 13%. The projected CAGR for the next 3 years is 8%.

Pre-Tax Income
Forecast

13% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-24%
Average Miss
13% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-24%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 13%. The projected CAGR for the next 3 years is 19%.

Net Income
Forecast

14% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-24%
Average Miss
14% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-24%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 14%. The projected CAGR for the next 6 years is 4%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is AMPH's stock price target?
Price Target
22.95 USD

According to Wall Street analysts, the average 1-year price target for AMPH is 22.95 USD with a low forecast of 20.2 USD and a high forecast of 31.5 USD.

What is the Revenue forecast for Amphastar Pharmaceuticals Inc?
Projected CAGR
3%

Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 6 years is 3%.

What is the Gross Profit forecast for Amphastar Pharmaceuticals Inc?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 11%. The projected CAGR for the next 3 years is 6%.

What is the Operating Income forecast for Amphastar Pharmaceuticals Inc?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Operating Income has been 13%. The projected CAGR for the next 3 years is 8%.

What is the Pre-Tax Income forecast for Amphastar Pharmaceuticals Inc?
Projected CAGR
19%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 13%. The projected CAGR for the next 3 years is 19%.

What is the Net Income forecast for Amphastar Pharmaceuticals Inc?
Projected CAGR
4%

Over the last 13 years, the compound annual growth rate for Net Income has been 14%. The projected CAGR for the next 6 years is 4%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett